Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.58 |
| ▸ | NPY2R | P49146 | 3/20 | 0.58 |
| ▸ | NPY4R | P50391 | 3/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486221 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29434320 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL3486226 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29388140 | 0.94 | GHSR (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29534023 | 0.94 | GHSR (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL14509563 | 0.91 | GHSR (0.65) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL31404052 | 0.90 | GHSR (0.68) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL21185972 | 0.90 | IL23R (0.65) | KISS1RIL23R | |
| SCHEMBL16358972 | 0.88 | GHSR (0.61) | GHSRUTS2R | |
| SCHEMBL30053610 | 0.88 | GHSR (0.71) | GHSRNPY1RNPY2RNPY4RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207212-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | UNIVERSITY OF MASSACHUSETTS | 2024-06-27 | — | — | US | disclosed |
| US-11865093-B2 | Methods and compositions for treating inflammation | UNIVERSITY OF MASSACHUSETTS (US) | 2024-01-09 | — | — | US | disclosed |
| US-11707486-B2 | Natural killer cell expressing anti-cotinine chimeric antigen receptor | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707486-B2 | Natural killer cell expressing anti-cotinine chimeric antigen receptor | PBK, KLK3, KLRK1 | GHSR 1697/4885NPY1R 3679/4885NPY2R 3693/4885 |
| US-11865093-B2 | Methods and compositions for treating inflammation | ABCC3, ABCC1, ABCE1 | GHSR 3386/4885NPY1R 2917/4885NPY2R 2548/4885 |
| US-20240207212-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | ABCC3, ABCC1, ABCE1 | GHSR 3386/4885NPY1R 2917/4885NPY2R 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.